Recruiting

NCT Number: NCT05875103

The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task

Verbal fluency test require to produce as much words as possible in one or two minutes. This test is highly sensitive to main brain diseases and are therefore widely used in clinical routine for diagnostic purpose. The verbal fluency task requires several cognitive processes including executive and linguistic processes for which it is difficult to extract the origin of the deficit. For this reason, fluency tests are variably interpreted in terms of executive or language. The implementation of an experimental protocol exploring each of these processes separately and studying the links between the verbal fluency task and each of these processes should allow a better understanding of the origin of the verbal fluency deficit after brain injury and improve the identification of key brain structures.

Indeed, the lesion determinants of this task remain to be clarified despite remarkable advances due to the evolution of imaging techniques (voxel-based lesion-symptom mapping (VLSM); voxel-based morphometry (VBM)).

Furthermore, while the direct assessment of linguistic process, semantic memory, and processing speed is well defined, the examination of the executive component (i.e., strategic search process) remains unsettled and will be undertaken in this study.

This work will take advantage of data from previous multicenter work, validated methodologies for both analysis and interpretation of cognitive performance as well as anatomic-clinical correlations at the voxel level and will be performed in cognitive neurodegenerative and cerebrovascular disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cognitive Neurodegenerative Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Communication Disorders Language Disorders Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Speech Disorders Stroke Vascular Diseases Verbal Fluency Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens

Amiens, 80054, France

Location status: Recruiting

Location contact

Martine Roussel, PhD

CONTACT

[email protected]

0322667813

Olivier GODEFROY, Pr

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For Cognitive cortical neurodegenerative diseases PATIENTS
informed consentPatients between 40 and 85 years old,
French native language,
Social Security affiliation,
Can read, write and count (up to 36) and knows the alphabet
Assessed in Amiens University Memory Clinic for:
Mild severity impairment (MMSE> 19) or major severity impairment related to:
AD according to Albert criteria and McKhann criteria
DCL according to McKeith criteria
FTLD according to Rascovsky criteria
CBD according to Armstrong's criteria
PSP according to Höglinger criteria
For Stroke PATIENTS
informed consent
Patients between 40 and 85 years old,
French native language,
Social Security affiliation,
Can read, write and count (up to 36) and knows the alphabet
Having suffered a stroke, hospitalized in neurology, visualized by imaging

Exclusion criteria

Mental retardation or guardianship
Other current or past brain condition affecting cognition, including:
Severe head trauma
Epilepsy prior to stroke still requiring previous treatment
Parkinson disease, multiple sclerosis
Brain tumor or brain radiation therapy
Current or past schizophrenia or psychosis
Active or past psychiatric impairments requiring a stay> 2 days in a specialized environment
Contra indication to MRI
Comorbidity with life expectancy <1 year
Comorbidity affecting cognition in particular:
Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
Opiate or cocaine addiction or opiate withdrawal syndrome
Renal failure (dialysis or creatinine clearance <30)
Hepatic failure (spontaneous INR> 1.5 or PT <60%)
Respiratory failure requiring oxygen therapy
Heart failure (orthopnea> 2 pillows)
Persistent vigilance disorder (NIHSS1a score ≤1)
Cancer with paraneoplastic syndrome
Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
Patient under guardianship or curators or private under public law
Pregnant and / or lactating woman

Treatment and study plan

linguistic processes

Diagnostic Test

Linguistic processes are assessed by performance score on the following tests:

naming tests : BNT 34 (Colombo & Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)
vocabulary test (Mill Hill - Deltour, 1993),
repetition tests (Gremots - Bézy et al., 2016),
articulatory speed (Majerus, 2014 ; Roussel et al., 2012)
semantic matching task adapted from the PPT (Howard & Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),
semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),
phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)

Primary outcomes

Corelation between Linguistic test performance score and verbal fluency score

Time frame: 1 hour
Linguistic processes are assessed by performance score on the following tests:
- BNT 34 and semantic naming adapted from the BECS-GRECO
- vocabulary test
- repetition tests
- articulatory speed
- semantic matching task adapted from the PPT and from the BECS-GRECO
- semantic categorization and attributes adapted from the BECS-GRECO
- phonologic and semantic research tasks adapted from the color TMT

Study contacts

Contact information is provided by the study sponsor or research team.

Martine ROUSSEL, PhD

CONTACT

[email protected]

0322668240

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: FluLEx

Important dates

Study start: 2023
Primary completion: 2029
Study completion: 2029
First posted: May 25, 2023
Registry last updated: May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed